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Background: There is a general concern that aged organs are more susceptible to ischaemia. In the light
of recent proposals to change the liver allocation system by expanding regional sharing, it is feared that
increased cold ischaemia time of grafts from older donors may reduce graft survival. The aim of this study
was to correlate donor age and the patterns of ischaemia reperfusion injury and synthetic function early
after liver transplantation.
Methods: We performed a retrospective study of first transplants using a single-centre electronic
database. Patterns of liver injury (based on transaminases and post-reperfusion biopsy), synthetic
function (international normalized ratio [INR]), and graft and patient survival in recipients receiving liver
grafts from donors aged 65 years (group 1, n = 50) were compared with equivalent patterns in a
matched cohort of recipients transplanted with grafts from donors aged <65 years (group 2, n = 50).
Results: There was no significant difference in transaminase levels from day 0 to day 6 after transplan-
tation. When groups 1 and 2 were subdivided into two subgroups based on the duration of graft cold
ischaemia time (<8 h and 8 h), there was no statistical difference in transaminase levels during the first
7 days. There were two cases (4%) of primary non-function in group 1 and one (2%) in group 2. Initial poor
function did not differ significantly between the groups (26% vs. 24%; P = 0.81). In addition, there was no
difference in histological changes in post-reperfusion biopsies (21% vs. 34%; P = 0.078) and rate of acute
rejection episodes in the first year (30% vs. 32%; P = 0.99). There was no significant difference between
groups 1 and 2 in 1-year patient and graft survivals (78% vs. 90% [P = 0.17]; 88% vs. 94%
[P = 0.48], respectively).
Conclusions: Judiciously selected livers from aged donors are not associated with major increased
susceptibility to ischaemia reperfusion injury.
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Introduction
Because of a shortage of organs, livers from older donors have
been increasingly used for transplantation. In the USA, the
number of liver donors aged 65 years increased from 0.1% to
10.2% during 1988 to 2005.1 According to the Organ Procurement
and Transplantation Network (OPTN), in 2009, liver donors aged
65 years represented 8.9% of all donors.
An old liver graft is considered an independent risk factor for
mortality after transplantation.2 The age of the donor is also a
predictive factor for the severity of recurrent liver hepatitis C virus
(HCV)-related disease on the graft.3 In addition, there is a general
concern that aged organs are more susceptible to ischaemia. In the
light of recent proposals to change the liver allocation system by
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expanding regional sharing, it is feared that increased cold
ischaemia time (CIT) of grafts from older donors might reduce
graft survival. The aim of this study was to correlate donor age and
the patterns of ischaemia reperfusion injury (IRI) and synthetic
function early after liver transplantation.
Materials and methods
We performed a retrospective study of first liver transplants using
a single-centre electronic database. Completeness of the database
was above 95%. Retrospective analysis showed that the power of
the study for survival analysis was 75–80%. This study analysed
data for randomly selected non-consecutive liver transplants that
met our inclusion criteria and were performed between January
2004 and December 2007 at Westchester Medical Center, New
York. During this period our centre performed 324 liver trans-
plants, 17% of which used organs from donors aged65 years. A
total of 76% of the grafts were procured by our team. Patterns of
liver injury (based on transaminases), synthetic function (INR
[international normalized ratio]) and cholestasis (bilirubin,
gamma-glutamyl transferase [GGT], alkaline phosphatase [AP])
during the first week, and at days 30 and 60 post-transplant, as
well as graft and patient survival at days 7, 30 and 60 in recipients
receiving liver grafts from donors aged65 years (group 1, n = 50)
were compared with equivalent patterns in a matched cohort of
recipients transplanted with grafts from donors aged <65 years
(group 2, n = 50). We included all transplants during this period
that used older donors and met our inclusion criteria (n = 50). By
contrast, transplants from the younger group of donors were
selected (n = 50). The selection procedure was blinded to recipient
and donor demographics and outcomes.
We analysed the following graft and donor parameters: CIT;
warm ischaemia time; cytomegalovirus (CMV) status; body mass
index (BMI); cause of death; donor risk index (DRI); total biliru-
bin; GGT; ALT (alanine aminotransferase); AST (aspartate ami-
notransferase); creatinine, and blood urea nitrogen (BUN).
Recipient parameters analysed were: age; sex; Model for End-stage
Liver Disease (MELD) score; cause of end-stage liver disease
(ESLD); creatinine, and pre-transplant transaminase and biliru-
bin levels. In a separate analysis we divided these groups in two
subgroups based on graft CITs of 8 h and <8 h.
A recipient was classified as experiencing primary non-function
(PNF) if he or she died or required retransplantation within the
first 7 days in the absence of an identifiable cause (e.g. hepatic
artery thrombosis, massive haemorrhagic necrosis), and as having
initial poor function (IPF) if his or her AST level was >1500 U/l
and prothrombin time was >20 s in the first postoperative week.4
Donor and recipient selection
At our institution, deceased donor livers are excluded from use
according to the presence of: positive HIV or human T cell lym-
photrophic virus serologies; most cases of donor malignancy, and
poor organ quality based on the opinion of an experienced liver
transplant surgeon on inspection of the organ or on histological
findings in selected cases. Donors were selected based on bio-
chemical, clinical and surgical (visualization/palpation of the liver
during harvesting, quality of perfusion) factors. The subjective
assessment of grafts from older donors is important in the
decision-making process and grafts of questionable quality,
including those with extensive atherosclerosis of the hepatic
artery, are rejected. We also avoid transplanting grafts from older
donors in HCV patients. Grafts that are positive for HCV are
considered for HCV-positive recipients if the biopsy is normal or
shows only stage I fibrosis. We try to minimize additional risk
factors and CIT when using grafts from older donors. All cases
involving organs from cardiac death donors, organs from live
donors, partial grafts, paediatric recipients (<18 years), kidney
and liver recipients, acute liver failure as indication and liver
retransplants were excluded from analysis. Patients with hepato-
cellular carcinoma (HCC) were listed for transplant according to
the Milan criteria.5 This analysis was performed after implemen-
tation of the MELD allocation system (February 2002). The
MELD score utilized referred to the physiological or native MELD
based on laboratory values obtained shortly prior to transplanta-
tion and not from adjustments for exception points (e.g. HCC
points). Donor risk index was calculated according to standard
formulae.6 About 76% of the liver grafts were procured by our
team. All allografts were preserved in University of Wisconsin
solution using established methods. The allocation of older grafts
was decided by the senior author on a case-by-case basis (depend-
ing on ABO group, quality of life, HCC status, co-morbidities,
etc.) and depending on the previous provision of informed
consent to the transplantation of an extended criteria organ
signed by the transplant candidate.
Transplant technique and immunosuppression
Patients were transplanted using the classical technique (removal
of the retrohepatic inferior vena cava). A veno–venous bypass was
used in a minority of cases. Recipients received tacrolimus, myco-
phenolate mophetyl and methylprednisone (and, later, pred-
nisone) as postoperative immunosuppression. If renal function
was impaired pre-transplant, patients received induction with
thymoglobulin and tacrolimus administration was postponed.
Histopathological analysis
Post-reperfusion biopsy specimens were obtained within 1 h after
complete revascularization of the allograft in most of the patients.
All biopsy specimens were fixed in 10% buffered formalin, pro-
cessed, embedded in paraffin, and stained with haematoxylin and
eosin before assessment. The severity of IRI was assessed by one
pathologist qualitatively as significant or non-significant based on
graft infiltration by acute inflammatory cells, ballooning degen-
eration, and the presence of coagulative necrosis. We did not
conduct protocol biopsies. Biopsies were taken when transami-
nases and cholestatic parameters were suggestive of rejection.
Assessment of acute cellular rejection in the first year post-
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transplant was carried out quantitatively (using a scale of 0–9),
but, for the sake of statistical power, we divided our patients into
only two groups: those with acute rejection and those with no
acute rejection episodes.
Statistical analysis
Unless specified otherwise, data are presented as mean standard
error of the mean (SEM). Normal distribution was assessed with
the Kolmogorov–Smirnov test. Differences between groups were
assessed with Student’s t-test for normally distributed variables.
Differences between groups were assessed with non-parametric
Mann–Whitney–Wilcoxon tests for non-Gaussian distributed
variables (DRI, creatinine, GGT, AST, ALT, bilirubin, INR). Com-
parisons of multiple groups were made using the Kruskal–Wallis
test. Categorical variables (cause of death, race, gender, CMV
status, aetiology of cirrhosis, HCC status, IRI, acute rejection,
retransplantation rate) were assessed using Fisher’s exact test. Sur-
vival analysis (1-year patient survival and rejection-free survival
within the first year) was performed using the Kaplan–Meier
method. Survival curves were compared using the log-rank
(Mantel–Cox) test. Differences were considered statistically sig-
nificant when the P-value was <0.05. The statistical software used
was GraphPad Prism for Windows Version 5.00 (GraphPad
Software, Inc., San Diego, CA, USA).
Results
There was no significant difference between the two recipient
groups before transplant except in MELD scores (Table 1). Older
grafts were more likely to be allocated to recipients with low
MELD scores (18.02 7.34 vs. 25.77 10.55; P < 0.0001). There
was no difference in the HCV status of recipients between the two
groups because about 50% of our liver transplant candidates are
HCV-positive and in the early phase of the study we were more
liberal in allocating older organs to HCV patients. Over the study
period there was no statistically significant difference in CIT
despite the intention to reduce it to a minimum when allocating
older grafts. Mean CIT was 7.7 h (range: 2–12 h) for younger
grafts and 7.3 h (range: 2–11 h) for older grafts. The fact that there
was no difference in CIT was partially associated with a more
liberal approach in the earlier period of this study. The mean age
of donors aged 65 years was 73.94 years (median: 72.5 years,
range: 65–86 years); the mean age of donors aged <65 years was
41.9 years (median: 45.5 years, range: 18–64 years). The donor
groups differed in: DRI; cause of death; gender; CMV status, and
transaminases (Table 2). The fact that there were no differences
between groups in CIT, BMI, cause of death or race allowed us to
test the effect of donor age as the main determinant of IRI. Donors
aged 65 years had a higher DRI (2.17  0.44 vs. 1.46  0.44;
P = 0.0001), were less likely to have died of trauma (10% vs. 26%;
P = 0.05) or anoxia (4% vs. 26%; P = 0.004), were more frequently
female (70% vs. 42%; P = 0.0085), were more frequently CMV-
positive (76% vs. 52%; P = 0.021), and had lower pre-procurement
transaminase levels (AST: 66.39  16.72 vs. 103.54  19.25
[P = 0.006]; ALT: 47.68  11.52 vs.130.06  33.86 [P = 0.0004]).
There were two cases (4%) of PNF in the group that received older
grafts and one (2%) in the group that received younger grafts. The
incidence of IPF did not differ significantly between the groups
Table 1 Liver donor characteristics
Donors aged <65
years (n = 50)
Donors aged 65
years (n = 50)
P-value
Age, mean  SD, years 41.9  14.5 (median: 45.5) 73.9  7.0 (median: 72.5) <0.0001
Gender 42% F, 52% M 70% F, 30% M 0.0085
Race 54% W, 18% AA, 16% H, 2% A 44% W, 8% AA, 26% H, 2% A >0.05 (NS)
Body mass index, mean  SD 28.7  5.4 28.6  5.9 0.89 (NS)
Cold ischaemia time, mean  SD, min 461.6  168.8 439.0  125.2 0.45 (NS)
Warm ischaemia time, mean  SD, min 45.9  7.5 46.0  8.2 0.93 (NS)
Cytomegalovirus+ 42% 76% 0.021
Cause of death Trauma 25% Trauma 10% 0.05 (NS)
Stroke 26% Stroke 86% <0.001
Anoxia 26% Anoxia 4% 0.004
Donor risk index, mean  SEM 1.46  0.04 2.17  0.04 0.0001
Creatinine, mean  SEM 1.6  0.2 1.5  0.2 0.67 (NS)
GGT, mean  SEM 78.2  13.1 62.3  12.5 0.97 (NS)
AST, mean  SEM 103.5  19.2 66.4  16.7 0.006
ALT, mean  SEM 130.1  33.9 47.7  11.5 0.0004
Total bilirubin, mean  SEM 1.1  0.1 0.8  0.1 0.04
F, female; M, male; W, White; AA, African-American; H, Hispanic; A, Asian; SD, standard deviation; SEM, standard error of the mean; GGT,
gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NS, not significant
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(26% vs. 24%; P = 0.81). There was no mortality in the first
post-transplant week in either group.
There was no significant difference in transaminase levels from
day 0 to day 5 after transplantation, or at days 30 and 60 (Fig. 1).
However, at day 6, recipients of older grafts presented higher AST
(157.29 43.56 vs. 86.04 8.97; P = 0.01) Total bilirubin did not
differ between groups in the first 5 days. On days 6 and 7, older
grafts were associated with higher bilirubin levels (day 7: group 1,
7.32  0.93; group 2, 4.14  0.55; P = 0.004) (Fig. 1). Increased
transaminases and bilirubin at this point indicate that aged grafts
may facilitate activation of antigen-specific effector arms of the
immune system. Interestingly, transaminases and cholestatic
parameters (total bilirubin and GGT) were not significantly
higher at 1 year in group 1 recipients that in group 2 recipients. In
addition, there was no difference in synthetic function (based on
INR and albumin values) during the first week, at days 30 and 60,
and at 1 year (Table 3).
When the older and younger graft groups were each divided
into two subgroups based on the duration of graft CIT (8 h and
<8 h), we again observed no statistical difference in levels of AST,
ALT, bilirubin and INR during the first 7 days (Fig. 2). These
results show that there was no additive or synergistic association
between advanced donor age and longer CIT.
Rates of retransplantation within 1 year were similar in both
groups (group 1: n = 3, 6%; group 2: n = 2, 4%; P = 1.0). Mortality
in the first 60 days and at 1 year was higher in recipients of older
livers (group 1), but this difference did not reach statistical sig-
nificance (12% vs. 6% [P = 0.48], 22% vs. 10% [P = 0.17], respec-
tively). The most common cause of death in both groups was
sepsis (Fig. 3).
Histologically, there was no difference in the occurrence of
significant IRI or in the time and number of acute cellular rejec-
tion episodes between younger and older grafts (Table 4, Fig. 4).
Discussion
Liver ageing and ischaemia reperfusion injury
The ageing process causes important anatomic and functional
changes in a number of systems that result in the reduction of
functional reserve and inability to cope with stress. The ageing
process is associated with changes in the intracellular redox
balance that occur as a consequence of reduced capacity to
produce active heat-shock proteins.7–9 It has been shown that there
is a shift toward the production of pro-inflammatory cytokines
(interleukin-6 [IL-6], IL-1, tumour necrosis factor-a, interferon-
g).10,11 Investigation in animal models showed that increasing age
is associated with increased IRI.12,13 Previous clinical reports have
also suggested that old age of the donor is associated with
increased IRI and, consequently, PNF, delayed graft function and
rejection.2,4,14–20 In an analysis of 7988 liver transplantations from
the United Network for Organ Sharing (UNOS) registry, donor
age >50 years was associated with a 7.1% decrease in 6-month
retransplantation-free survival (69.0% vs. 76.1%).14 However,
other factors, such as susceptibility to acute rejection and biliary
complications, may be responsible for these poorer results. Several
studies have shown that older grafts are more immunogenic and
more susceptible to acute and chronic rejection (for review, see21).
It has been postulated that IRI can potentiate the immunogenicity
of the graft by releasing ‘danger signals’, leading to the recruitment
of inflammatory cells that promote acute rejection.21,22 In kidney
transplantation, but not in liver transplantation, there is a clear
Table 2 Recipient characteristics
Recipients of donor grafts
aged <65 years (n = 50)
Recipients of donor grafts
aged 65 years (n = 50)
P-value
Age, mean  SD, years 53.3  14.6 (median: 55) 57.6  11.2 (median: 61) 0.082 (NS)
Gender 44% F, 56% M 38% F, 52% M 0.47 (NS)
Race 50% W, 10% AA, 26% H, 4% A 44% W, 8% AA, 24% H, 4% A >0.05 (NS)
Body mass index, mean  SD 27.8  5.4 28.1  3.6 0.81 (NS)
MELD, mean  SD 26.0  10.6 19.8  9.2 0.003a
Aetiology of cirrhosis Alcohol 12% Alcohol 20% >0.05 (NS)
HCV 48% HCV 42% >0.05 (NS)
HBV 8% HBV 0% >0.05 (NS)
Other 32% Other 38% >0.05 (NS)
Hepatocellular carcinoma 10% 10% >0.05 (NS)
AST, mean  SEM 148.8  9.7 88.4  10.8 0.21 (NS)
ALT, mean  SEM 164.9  102 74.5  19.8 0.56 (NS)
Total bilirubin, mean  SEM 7.7  1.1 6.3  0.7 0.30 (NS)
INR, mean  SEM 2.3  0.2 1.8  0.1 0.06 (NS)
aThe two groups differ only on MELD scores. Older grafts were allocated more frequently to recipients with lower MELD scores
F, female; M, male; W, White; AA, African-American; H, Hispanic; A, Asian; MELD, Model of End-stage Liver Disease; SD, standard deviation; SEM,
standard error of the mean; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR,
international normalized ratio; NS, not significant
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correlation between older organs and IRI (acute tubular necrosis).
The use of kidneys from older donors is associated with an
increased risk for delayed graft function and acute rejection.23 The
difference between the liver and other organs may be related to the
liver’s regenerative and immunomodulatory capacities.24,25 It is
also believed that the liver suffers little decrease in function with
ageing.26–29 Rosen et al. demonstrated that rejection is not related
to the extent of IRI in liver transplant patients.30 These authors
showed that short-term graft survival is proportional to the extent
of IRI only when it is extreme (ASTmax >5000 U/l), but grafts that
are not lost to PNF have equivalent 1- and 2-year survival rates,
irrespective of the magnitude of IRI. Rosen et al. also showed that
40% of grafts with extreme IRI are lost to PNF, but the same
proportion also provide longterm function; in surviving grafts,
longterm biochemical function and incidence of biliary compli-
cations and chronic rejection are unrelated to the extent of IRI.30
In another study, glutathione content, the main hepatic-free
radical scavenger, measured at the time of early reperfusion, was
similar in livers obtained from young and elderly (>60 years)
cadaveric donors.31 In a small study involving 16 liver transplants
from donors aged >50 years, Deschênes et al. showed the use of
older grafts to be associated with more histology-proven extensive
ischaemic damage immediately after reperfusion, but there was no
statistically significant difference between the severity of the
damage and the incidence of IPF.32 In a rat model of liver trans-
plantation Sakai et al. showed that recipients of young and old
livers after 30 h of cold preservation had identical survival rates
(60%) and no difference in the peak of AST.33
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Figure 1 Seven-day curves showing (A) AST (aspartate aminotransferase), (B) ALT (alanine aminotransferase), (C) total bilirubin and (D) INR
(international normalized ratio) in recipients of grafts aged 65 years vs. recipients of grafts aged <65 years (n = 50 per group). AST and
bilirubin levels in recipients of grafts from older donors were significantly elevated only at days 6 and 7 (P = 0.01, P = 0.01 and P = 0.002,
P = 0.004, respectively). ALT and INR levels did not differ significantly between the two groups in the first 7 days. Error bars represent the
standard error of the mean
Table 3 Total bilirubin, GGT and INR values at 30 days, 60 days and 1 year after liver transplantation
30 days P-value 60 days P-value 1 year P-value
Graft aged
<65 years
Graft aged
65 years
Graft aged
<65 years
Graft aged
65 years
Graft aged
<65 years
Graft aged
65 years
Total bilirubin,
mean  SEM
1.2  0.1 2.9  0.6 0.001 1.2  0.4 1.7  0.4 0.009 1.5  0.5 1.5  0.4 0.53
GGT, mean  SEM 132.4  19.0 244.4  32.5 0.0004 133.7  23.6 190.0  38.8 0.09 170.2  43.7 164.2  35.3 0.62
INR, mean  SEM 1.1  0.03 1.1  0.02 0.59 1.1  0.14 1.1  0.09 0.38 1.0  0.04 1.2  0.10 0.17
Bilirubin and GGT levels in recipients of grafts from older donors were significantly elevated at day 30 after transplant, but did not differ from those
in recipients of younger grafts at day 60 and 1 year after transplantation
GGT, gamma-glutamyl transferase; INR, international normalized ratio; SEM, standard error of the mean
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Clinical outcomes of older grafts and impact of IRI
Until the late 1980s, organs from donors aged >50 years were rarely
used.34 However, the discrepancy between demand and supply
imposed the use of high-risk donors, including elderly donors.
Extended criteria grafts are especially used in patients with poorer
prognoses who cannot wait long for a graft (e.g. subjects with
HCC) or who have poor quality of life and low MELD scores.
There are several reports showing inferior outcomes when using
older donors.4,31,35–37 Data from the OPTN for all liver transplants
performed in the USA between 1997 and 2004 showed that the
survival rates for both recipients and grafts from donors aged65
years are lower than those for recipients and grafts from donors
aged 18–34 years at 1 year (80.6% vs. 87.7%, and 74.2% vs. 84.2%,
respectively) and 5 years (66.1% vs. 76.5% and 51.6% vs. 70.4%,
respectively).38 However, single-centre analyses have failed to dem-
onstrate significant differences in short- and medium-term graft
and patient survival using donors aged >60 years,39–49 especially in
the absence of other donor risk factors and in carefully selected
recipients.46–49 In a large cohort study, Hoofnagle and colleagues
showed that the overall incidence of poor graft survival was more
common among recipients of older livers, but that recipients of
older liver grafts assessed as good by the procuring surgeon had a
retransplant-free survival similar to that of recipients of younger
livers (87% vs. 91% at 3 months). Thus, the utilization of selected
older livers was not associated with a decrease in patient or graft
survival.50 The same study found that although older donors were
more likely to have died of central nervous system-related causes
and to be CMV-positive, they also had some favourable character-
istics such as lower occurrences of pre-harvest episodes of acidosis,
hypoxemia and transfusions, as well as less chronic drug use and
acute alcohol intoxication. We have also shown in our study that
livers from older donors have lower transaminase and total biliru-
bin levels, and possibly have experienced less ischaemic insult
before harvesting as the incidence of death associated with hypoxia
in this group is significantly lower.
It is feared that regional sharing of livers might increase CIT and
reduce even further the survival of older grafts.51 In a retrospective
analysis of UNOS data from 18 787 liver transplants carried out
between 2002 and 2007 (post-MELD era), Cassuto et al. showed
that grafts from donors aged >60 years with longer CIT have
particularly reduced rates of survival.52 Compared with grafts from
a reference group (donors aged <60 years, CIT < 6 h), grafts aged
>60 years with CIT of >12 h had a 92.7% increased risk for overall
graft loss,whereas that for grafts aged <60 years with CIT > 12 h was
57.0%.52 Reese and colleagues, in a retrospective study of the UNOS
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Figure 2 Seven-day curves showing (A) AST (aspartate aminotransferase), (B) ALT (alanine aminotransferase), (C) total bilirubin and (D) INR
(international normalized ratio) in four groups of recipients of grafts aged 65 years or <65 years with cold ischaemia time of <8 h or 8 h.
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Figure 3 One-year patient survival curves after transplantation.
Although 1-year survival was lower in recipients of livers from donors
aged 65 years (78% vs. 90%), this difference did not reach statis-
tical significance (n = 50 per group; P = 0.13). The most common
cause of death in both groups was sepsis
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database of 44 742 liver transplants, demonstrated the effect of a
negative interaction between donor age >45 years and CIT > 12 h
on 90-day graft survival (17.3% vs. 11.1%; odds ratio [OR] 1.24, P
< 0.01), but this difference did not reach statistical significance in
the post-MELD era (OR 1.18,P = 0.38).19 Segev and colleagues also
used post-MELD UNOS data to compare the characteristics and
outcomes of 1357 liver transplants with prolonged CIT (>12 h)
with those of 13 280 transplants with CIT of <12 h.53 They noted
that donor age did not significantly amplify the risk for graft loss in
grafts with prolonged CIT. The only donor-related risk factor for
these grafts with increased CIT was African-American ethnicity.53
In a study of the UNOS data for 58 576 liver transplants, the rate of
PNF increased exponentially from the year 1990 (<1%) to 2000
(>6%), reflecting the more frequent use of ECDs. This rate
decreased after 2000 despite the increased use of older donors.42
Mangus et al. showed that outcomes of imported ECD grafts (with
longer CITs) were similar to those of locally procured grafts.54 This
would appear to be paradoxical, because a higher incidence of PNF
might be expected to occur under the MELD allocation system as
more morbid patients gain access to transplant. Exactly why the
impact of prolonged CIT in older grafts is reduced in the MELD era
is unclear and is probably multifactorial. It is likely that the
decreased rate of PNF may reflect not the changes in the system of
allocation, but, instead, increased experience in the selection and
allocation of ECD grafts. In our study, we did not investigate the
effect of regional allocation because <10% of all livers were
imported from other regions and all of them had CITs of <12 h. In
these circumstances, this study would have had very low power to
investigate the effect of transport on IRI. However, we investigated
the effect of different CITs (<8 h and 8 h) on graft and patient
outcomes.
Older organs may have a lower threshold for injury; however,
they have similar outcomes when transplanted within a certain
range of CIT. Data from the Eurotransplant Registry for 5002 liver
transplants using grafts from donors aged >65 years showed that
the survival difference between grafts with CIT of >12 h and grafts
with CIT of <12 h was only marginally significant (70% vs. 78% at
1 year, 59% vs. 60% at 5 years; P = 0.047) (Rene Adam, Eurotrans-
plant Registry, personal communication, 2009). A meta-analysis
by Stahl et al. showed that the relationship between CIT and PNF
is not linear.55 Primary non-function and graft and patient sur-
vival were worse for both very short and long CITs (<5 h and
>12.5 h). This probably represents a selection bias because the
sickest patients tend to receive organs with short CITs.55 Tekin
et al. also demonstrated an exponential rather than a linear
increase in graft dysfunction of ECD grafts when the CIT was
>12 h (45.5% vs. 15.0%).56 In our study, almost all grafts were
transplanted within 12 h, which may explain why outcomes in
younger and older grafts were similar.
The main limitations of our study concern its status as a ret-
rospective single-centre study and the small number of patients
(n = 50 per group). Retrospective studies are subject to selection
bias and details of clinical management and other data can be
incomplete or lacking. Although the magnitude of aminotrans-
ferase elevation in the early post-transplant period reflects the
extent of hepatocellular injury and has historically been used to
classify the severity of preservation injury,30 other measures of
IRI (quantitative histological assessment, functional and genetic
assays) were not used. Our study analysed only the effect of
donor age on IRI based on the fact that the two recipient popu-
lations were similar. However, the recipient groups differed in
MELD scores. Although recipient variables (MELD score,
co-morbidities) probably play a role in the ultimate severity of
IRI, donor- and preservation-related factors are likely to repre-
Table 4 Histopathological analysis
Ischaemia reperfusion injury P-value Acute cellular rejection P-value
Significant Not significant Present Absent
Grafts aged <65 years 11 (34%) 21 (64%) 16 (32%) 34 (68%)
0.078 0.99
Grafts aged 65 years 7 (21%) 26 (79%) 15 (30%) 35 (70%)
Post-reperfusion biopsy was assessed for the presence of significant ischaemia reperfusion injury (IRI). Acute cellular rejection within 1 year of liver
transplantation was assessed here only qualitatively (presence or absence of rejection). The number of grafts that showed significant IRI and acute
cellular rejection did not differ significantly between the groups
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Figure 4 Rejection-free survival within 1 year after transplantation
(time until first episode of biopsy-proven acute cellular rejection in the
first year). There was no difference between the two groups in the
timing and number of rejection episodes (n = 50 per group; P = 0.24)
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sent its major determinants.57 In our study, control of these vari-
ables was not possible. Randomization is particularly difficult in
a study that measures the effect of age on IRI because we cannot
randomly assign ECD organs in clinical transplantation. Patients
with high MELD scores usually receive better organs, whereas
older grafts are allocated to recipients with low MELD scores. In
addition, older grafts are preferably not allocated to HCV-
positive patients because HCV has been shown to have higher
recurrence rates.3
Although some reports of experiments in animal models have
suggested that aged organs are more susceptible to IRI, our analy-
sis was not able to identify any significant impact of donor age on
the incidence of IRI and short-term liver function. Ischaemia
reperfusion injury is probably not linearly correlated with CIT.
There may be a time-point at which the damage caused by cold
ischaemia becomes irreversible and this may compromise graft
function and survival. Although it is probable that older age of the
liver donor increases susceptibility to IRI by reducing this thresh-
old, these effects may not be clinically relevant when these donors
are strictly selected (e.g. by eliminating additional risk factors)
and CIT is minimized. Access to older donors will continue to
represent an important way of expanding the liver donor pool.
Large, prospective, observational multicentre studies are needed
to confirm these findings.
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